BLA vs NDA: FDA Application Types and What They Mean

You bought a gene therapy stock the week before its PDUFA date. The Phase 3 data was clean. The AdCom voted yes. The FDA issued a Complete Response Letter anyway - not because the data failed, but because the manufacturing process wasn’t consistent batch to batch. You didn’t know gene therapies file BLAs, and BLAs carry a kind of manufacturing risk that small molecule NDAs almost never do. That distinction cost you 40% in a day.

The solution: before you trade any biotech catalyst, you need to know whether the company is filing an NDA (New Drug Application) or a BLA (Biologics License Application). The application type tells you about manufacturing risk, exclusivity, biosimilar competition, and the kind of CRLs you’re exposed to. It takes two minutes to figure out, and most retail investors never bother.

Step 1: Learn the core distinction - chemical vs biologic

An NDA covers small molecule drugs: chemical compounds synthesized in a lab, typically pills. Think kinase inhibitors, protease inhibitors, antisense oligonucleotides. The molecule is well-defined, the synthesis is reproducible, and the FDA’s Office of Pharmaceutical Quality reviews the application.

A BLA covers biologics: drugs made from or inside living organisms. That includes monoclonal antibodies, gene therapies (AAV, lentiviral), cell therapies (CAR-T), vaccines, and recombinant proteins. The active ingredient is produced in living cells - bacteria, yeast, or mammalian cell lines - then purified. The FDA’s Office of Biotechnology Products reviews these. Because biologics are grown, not synthesized, every batch is slightly different. That variability is the source of most BLA-specific risk.

Step 2: Identify the filing type from the drug, not the press release

Companies don’t always say “BLA” or “NDA” in the headline. You can usually tell from the drug itself:

• Gene therapies (AAV, lentiviral) - BLA. Example: Vertex’s Casgevy (exagamglogene autotcemcel), the sickle cell gene therapy approved in late 2023 and expanded to children age 2 in 2024. See our Casgevy approval writeup.
• Monoclonal antibodies - BLA. Examples: Merck’s Keytruda (pembrolizumab), Daiichi-Sankyo/AstraZeneca’s Enhertu (trastuzumab deruxtecan), Eisai/Biogen’s Leqembi (lecanemab).
• CAR-T and other cell therapies - BLA.
• Vaccines - BLA. Example: Moderna’s mRNA-1010 flu vaccine, PDUFA August 5, 2026.
• Recombinant proteins - BLA.
• Small molecule kinase inhibitors and protease inhibitors - NDA. Example: Cogent’s bezuclastinib (systemic mastocytosis, PDUFA November 30, 2026).
• Antisense oligonucleotides and siRNA - NDA. Example: Ionis/AstraZeneca’s eplontersen (ATTR cardiomyopathy).

If the drug is a pill or a synthetic small molecule, it’s an NDA. If it’s grown in cells, delivered by a virus, or made from a protein, it’s a BLA. The boundary case is peptides - small peptides file as NDAs, large ones as BLAs.

Step 3: Understand the review pathway - same speed, different risk

Both NDAs and BLAs can get Priority Review (6 months) or Standard Review (10 months) from FDA acceptance. Both can receive accelerated approval on a surrogate endpoint - see our accelerated approval guide. Both can get Fast Track and Breakthrough Therapy designations. The application type doesn’t change review speed - the indication and unmet need do.

What changes is the risk profile. The overall CRL base rate is roughly 37% of NDAs and BLAs combined between 2018 and 2022 (Avalere / FDA user-fee data) - about one in three applications gets a Complete Response Letter. For BLAs, manufacturing deficiencies are a leading cause. For NDAs, manufacturing CRLs are rare because chemical synthesis is predictable. See our CRL guide for the typical 30 to 60% single-day stock drop.

The mechanics of how these deadlines get set are in our PDUFA date guide.

Step 4: Read the exclusivity clock - 12 years vs 5 years

This is the part most investors miss, and it matters for how long the revenue tail lasts.

• Small molecule NDAs get 5 years of Hatch-Waxman exclusivity from approval before a generic can be filed. After 4 years a generic company can file a paragraph IV challenge; generics typically launch at the 5-year mark.
• BLAs get 12 years of biologics exclusivity under the BPCIA (Biologics Price Competition and Innovation Act), with 4 years of data exclusivity on top. Biosimilars - not generics - follow BLAs, and biosimilars are far harder and more expensive to develop than small molecule generics. That extends the revenue tail for biologics materially.

The trade-off: biologics are riskier to manufacture, but if they get approved, the moat lasts longer. For a foundational walk through how this factors into biotech investing, see our How to Invest in Biotech Stocks guide.

Step 5: Watch BLA manufacturing CRL risk specifically

When you trade a BLA catalyst, manufacturing is a separate risk layer on top of efficacy and safety. The FDA inspects the manufacturing facility before approval, and biologics facilities fail more often than small molecule facilities because the process is harder to control.

Real example: Elevar Therapeutics’ rivoceranib (with camrelizumab) for unresectable hepatocellular carcinoma received its third CRL on July 23, 2026 - manufacturing deficiencies, not efficacy. The drug was already approved in China. The U.S. NDA resubmission was rejected on CMC (chemistry, manufacturing, and controls) grounds. See our Elevar third CRL writeup. If you were trading the PDUFA on efficacy alone, you mispriced the catalyst.

For BLAs, the same risk shows up as facility inspection failures, batch consistency issues, and stability data gaps. None of those are visible in the clinical trial press release.

Step 6: Learn sBLA and sNDA for label expansions

Once a drug is approved, the company files supplemental applications to expand the label - new indications, new patient populations, new dosing.

• sBLA = supplemental BLA (for an approved biologic).
• sNDA = supplemental NDA (for an approved small molecule).

Real example: Merck/Daiichi-Sankyo filed an sBLA for Enhertu in HER2+ early breast cancer (post-neoadjuvant), PDUFA July 7, 2026 - approved that day. Real example on the NDA side: MannKind’s FUROSCIX ReadyFlow sNDA for subcutaneous furosemide autoinjector, approved July 26, 2026.

Label expansion PDUFAs are usually lower-risk than initial approvals because the drug is already on the market and the safety profile is known. But they can still be binary on the new indication data.

Common mistakes

• Treating every PDUFA as the same trade. A small molecule NDA PDUFA and a gene therapy BLA PDUFA have different risk profiles. The BLA has manufacturing risk layered on top of efficacy risk.
• Ignoring manufacturing facility inspections. For BLAs, the FDA’s pre-approval inspection can sink the application regardless of the clinical data. Check whether the manufacturing facility has a recent Form 483 or warning letter on FDA.gov.
• Assuming exclusivity is the same for both. Five years for small molecules, twelve for biologics. That affects how long the revenue tail lasts and how you value the asset.
• Confusing biosimilars with generics. Biosimilars cost hundreds of millions to develop and rarely launch at the 80%+ discounts generics do. BLA revenue tails erode slower.
• Trading an sBLA like an initial BLA. Supplemental applications for label expansions are usually lower-risk than first approvals. Don’t pay the same run-up premium.

Final checklist

• Application type identified (BLA for biologics, NDA for small molecules)
• Manufacturing facility inspection history checked for BLAs
• Exclusivity period noted (5 years NDA, 12 years BLA)
• Review type confirmed (Priority 6 months, Standard 10 months) on FDA user-fee programs
• Supplemental vs initial application identified (sBLA/sNDA are usually lower-risk)
• PDUFA date confirmed and position sized for a 50% loss - see our FDA catalyst trading guide